Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
ACW
vs
S
S&P/ASX 300
ACW
Over the past 12 months, ACW has significantly outperformed S&P/ASX 300, delivering a return of +69% compared to S&P/ASX 300's 3% drop.
Stocks Performance
ACW vs S&P/ASX 300
Performance Gap
ACW vs S&P/ASX 300
Performance By Year
ACW vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Actinogen Medical Ltd
Glance View
Actinogen Medical Ltd is a clinical-stage biotechnology company focused on drugs for brain diseases. Its main program is Xanamem, a tablet medicine designed to reduce excess cortisol activity in the brain, which the company is studying for conditions such as Alzheimer’s disease and other cognitive disorders. In simple terms, it is trying to turn a science idea into a prescription treatment for memory and thinking problems. The company does not sell a broad range of commercial products yet. Instead, it earns value by advancing its drug candidates through laboratory work and human trials, then seeking larger partners, licensing deals, or eventual drug approval if the studies succeed. Its main customers are not everyday consumers today, but future patients, doctors, and healthcare systems that could use the medicine if it reaches the market. Actinogen sits in the risky but potentially valuable part of the drug industry where companies fund research, run trials, and build evidence before any sales begin. That business model is different from a normal manufacturer because most of the work is tied to proving that one or a few medicines are safe and effective, rather than selling lots of products at once.